Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Summary

This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant chemo-radiotherapy with weekly cisplatin for at least five weeks.

Timeline

Start

2018-09-05

Primary completion

2023-03-01

Completion

2023-04-15

Publications

• Detlefsen SS, Andersen DS, Knudsen AO, Nottrup TJ, Moller S, Nyvang GB, Jorgensen TL, Herrstedt J, Ruhlmann CH. Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study. Support Care Cancer. 2025 May 28;33(6):509. doi: 10.1007/s00520-025-09573-9.

Drugs

Indications